ArticleBMC biotechnology2010
Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies.
Article in BMC biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Single-cell RNA sequencing of circulating tumour cells in colorectal cancer.Molecular biology reports · 2026Article
- Circulating Tumor Cells for the Monitoring of Lung Cancer Therapies.International journal of molecular sciences · 2025Review
- Precision Oncology Framework Using Circulating Tumor Cells.International journal of molecular sciences · 2025Review
- Label-free microfluidic enrichment of cancer cells from non-cancer cells in ascites.Scientific reports · 2021Article
- Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells.Cells · 2020Review
- Biology and clinical relevance of EpCAM.Cell stress · 2019Review
- Review
- Quantitative proteomic profiling of paired cancerous and normal colon epithelial cells isolated freshly from colorectal cancer patients.Proteomics. Clinical applications · 2017Article
- Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy.Molecular and clinical oncology · 2017Article
- Circulating tumor cells in thyroid carcinoma - the prognostic role of this biomarker. Review of the literature.Clujul medical (1957) · 2017Review
- Clinical applications of liquid biopsies in gastrointestinal oncology.Journal of gastrointestinal oncology · 2016Review
- Circulating tumor cells isolation: the "post-EpCAM era".Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Review
- Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Article
- Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.The Journal of molecular diagnostics : JMD · 2015Review
- Benchtop technologies for circulating tumor cells separation based on biophysical properties.BioMed research international · 2015Review
- Prognostic relevance of minimal residual disease in colorectal cancer.World journal of gastroenterology · 2014Review
- Article
- Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells.Cancer research · 2013Article
- The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer.PloS one · 2013Article
- Isolated, disseminated and circulating tumour cells in prostate cancer.Nature reviews. Urology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumor cells (CTC) and disseminated tumor cells (DTC) are thought to be responsible for metastasis, so the detection of CTC may serve as individual prognostic factor in patients suffering from colorectal cancer. Therefore, a series of immunomagnetic enrichment methods for CTC have been developed using a variety of monoclonal antibodies against the Epithelial Cell Adhesion Molecule (EpCAM). However, it remains unclear whether all commercially available EpCAM antibodies show the same sensitivity and specificity. Furthermore, it remains unclear which method of sample preparation and cell extraction is most suitable for immunomagnetic enrichment and detection of CTC. In this study, we aimed to investigate whether the detection of CTC by a cytokeratin 20 reverse transcriptase-polymerase chain reaction (CK20 RT-PCR) may be influenced by the use of various Epithelial Cell Adhesion Molecule (EpCAM) antibodies for immunomagnetic isolation of CTC.
resultsUsing both EpCAM antibodies (mAb BerEP4 and mAb KS1/4) for immunomagnetic enrichment in blood samples of 39 patients with colorectal cancer we found heterogenous results in each patient with regard to tumor cell detection. In the tumor cell spiking experiments with whole blood samples the sensitivity of the CK 20 RT-PCR assay was higher using immunomagnetic beads coated with mAb KS1/4 compared to precoated mAb BerEP4 Dynabeads. Extraction of MNC fraction with Ficoll gradient centrifugation prior to immunomagnetic enrichment resulted in a higher sensitivity of the CK 20 RT-PCR assay.
conclusionsWe concluded that isolation and detection of CTC with immunomagnetic enrichment methods is critically dependent on the used EpCAM clone. Further studies with a larger number of patients should clarify if the enrichment protocol influences the prognostic value of the tumor cell detection protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.